Genetic predisposition to chronic lymphocytic leukemia is mediated by a BMF super-enhancer polymorphism [PDF]
Gutiérrez Abril, Jesús +5 more
core +1 more source
Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential. [PDF]
Ann HematolPrajapati S +3 more
europepmc +1 more source
Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]
Oncol RevVisentin A, Mauro FR.
europepmc +1 more source
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort. [PDF]
Future OncolMunir T +10 more
europepmc +1 more source
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial. [PDF]
J Clin OncolSharman JP +4 more
europepmc +1 more source
Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis. [PDF]
Ann HematolXiong XY +5 more
europepmc +1 more source
Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-Type <i>FLT3</i> Acute Myeloid Leukemia/Myelodysplastic Neoplasms. [PDF]
Case Rep HematolChang S +7 more
europepmc +1 more source
Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single-Centre Real-World Experience. [PDF]
Cancer Rep (Hoboken)Çınar OE +5 more
europepmc +1 more source